
Asthma
Latest News
CME Content









Benralizumab has shown a greater reduction of eosinophil levels than that of mepolizumab and reslizumab, but whether or not it's a clinically significant finding is not yet told.

When inhaled, cinnamaldehyde can disrupt the lung's anti-bacterial defense system, exposing users to respiratory infection.

The longtime therapy Symbicort was tested for safety and efficacy versus SABA in 8000-plus patients on an as-needed treatment basis.

The administration of the treatment to asthma patients is fairly common, despite guidelines advocating against it under certain circumstances.

Sanofi and Regeneron reported promising results from a pair of pivotal phase 3 trials for the investigative add-on therapy.

From food deserts to hazardous jobs that inhibit exposure and limit the means to prevent it, people of low SES are at greatest environmental health risk.

Researchers intend to follow observed infants into early childhood to gauge the vitamin's influence on pediatric asthma rates.

Children given immunocap radioallergosorbent tests when hospitalized for asthma avoided re-hopsitalization twice as long as children not given the test.

The inhaled corticosteroid from GSK is indicated for pediatric asthma patients aged 5-11 years old.

Older people adhering to the antioxidant-rich diet were less likely die from cardiovascular conditions when exposed to greater ambient air pollution.

The monoclonal antibody reported quick and consistent exacerbation rate reduction in patients with severe eosinophilic asthma.

Over 16 months, a greater rate of patients reported returning visits, proper inhaler use understadning, and overall satisfcation.

The hazard ratios for ozone measured at bone as a single pollutant showed statistically significant higher risks for development of asthma, allergic rhinitis and eczema.

An association between antibiotic treatment in infancy and development of atopic asthma in childhood suggests an immune-mediated effect.

Ambient air pollution has become one of the world's greatest killers. But physicians still differ on their involvement in fighting it.

One inhalation product can be effective as a single maintenance and reliever therapy for asthma.

AstraZeneca announced that the first of its 2 phase 3 trials of benralizumab for severe COPD failed to meet its primary efficacy endpoint.









































































